CD19 and autoimmune neuropathy: Objective: To demonstrate the efficacy of autologous anti‐CD19 CAR T cell therapy in two severe cases of autoimmune neuropathies Methods: Two patients with a history of more than 12 months of severe tetraparesis with insufficient response to established immunotherapies were selected from our clinical cohort of autoimmune neuropathies.